Reducing Cardiovascular Disease-An Alternative Approach
- PMID: 38976144
- DOI: 10.1007/s10557-024-07600-1
Reducing Cardiovascular Disease-An Alternative Approach
Abstract
Purpose: Statin drugs are effective at reducing cardiovascular events, but adherence to statin therapy remains a problem for patients and their physicians. We review a paper estimating the economic costs of poor adherence to statin drugs.
Methods: The authors examined two large databases (Medicare and Market Scan databases) including 230,000 patients with hospitalization for myocardial infarction between 2018 and 2019 to determine how many patients were not adhering to guideline-recommended anti-hyperlipidemic medications. They have also calculated the potential consequences of patients who are not adhering to the recommended therapy.
Results: The authors estimate that if all patients were receiving guideline-directed medical therapy, then a 22% relative risk reduction would occur in the 3-year period following discharge from the initial cardiovascular event. These findings are consistent with prior reports. This editorial discusses rationale and strategies clinicians can use to improve patients' compliance with recommendations for lipid-lowering therapy.
Conclusion: The authors conclude that better compliance with guideline-directed lipid therapy after a cardiovascular event would lead to a large reduction in second events. Increased efforts by clinicians to improve adherence to statin therapy are warranted.
Keywords: Cardiovascular disease; Cardiovascular guidelines; Cardiovascular risk; Coronary atherosclerosis; Coronary intervention.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Ethics Approval: Not applicable. This manuscript did not involve human subjects, animals, or ethical issues. Thus, no ethics approval was obtained. Consent to Participate: Not applicable. This manuscript did not involve human subjects, so there was no consent to participate in this manuscript. Consent for Publication: Not applicable. No human subjects were involved in the preparation of this manuscript, so there was no one to give consent for publication. Conflict of Interest: The authors declare no competing interests.
References
-
- Sakhuja S, Bittner VA, Brown TM, et al. Recurrent atherosclerotic cardiovascular disease events potentially prevented with guideline-recommended cholesterol-lowering therapy following myocardial infarction. Cardiovasc Drugs Ther. 2023. https://doi.org/10.1007/s10557-023-07452-1 . - DOI - PubMed
-
- Nissen SE. Statin denial: an internet-driven cult with deadly consequences. Ann Intern Med. 2017;167:281–2. https://doi.org/10.7326/M17-1566 . - DOI - PubMed
-
- Kwok CS, Amin AP, Shah B, et al. Cost of coronary syndrome treated with percutaneous coronary intervention and 30-day unplanned readmission in the United States. Catheter Cardiovasc Interv. 2019;97:80–93. https://doi.org/10.1002/ccd.28660 . - DOI - PubMed
-
- Schade DS, Eaton RP. A simplified approach to reducing cardiovascular risk. J Clin Endocrinol Metab. 2019;104:6033–9. https://doi.org/10.1210/jc.2018-02509 . - DOI - PubMed
-
- Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA. 2004;291:1071. https://doi.org/10.1001/jama.291.9.1071 . - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources